Even though the U.S. CDC is operating on a skeleton crew due to the partial government shutdown, it is updating its immunization schedules to adopt the COVID-19 and chickenpox vaccine recommendations the Advisory Committee on Immunization Practices (ACIP) made at its September meeting.
Bacterial resistance remains one of the biggest obstacles to antibiotic efficacy and spurs the constant search for next-generation antimicrobials. Oxacins can kill bacteria by inhibiting the activity of DNA gyrase. As potential next-generation oxacin-like drugs, researchers at Southwest University and collaborators have developed thiazolylcyanovinyl benzopyridone acids, among which the ethyl compound [I] turned out to be effective at killing several gram-negative and -positive bacterial strains in vitro as well as Klebsiella pneumonia in biofilms. It also eliminated wound infection in mice, without causing obvious off-target toxicity.
While the discussions and votes at the past two meetings of the U.S. CDC Advisory Committee for Immunization Practices (ACIP) have generated a lot of controversy and resulted in some states and medical groups issuing their own vaccine schedules, the truth is that the newly reconstituted committee’s recommendations to date are still in line with, or more generous in some instances than, global norms.
Convalife Pharmaceuticals Co. Ltd. and Zhejiang Convalife Pharmaceutical Co. Ltd. have described benzoselenazepine compounds reported to be useful for the respiratory syncytial virus (RSV) infection.
Researchers from Nanjing Chengshi (TheraRNA) Biomedical Technology Co. Ltd. and collaborators have developed a novel ionizable lipid, C14-192, that features a 3-oxo-polyamine head group.
Appili Therapeutics Inc. and its partner Vitalex Biosciences LLC have announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded up to $40 million in funding to support the development of VXV-01, a vaccine aimed at protecting against invasive fungal infections.
Human rhinovirus (HRV) is the most frequent cause of upper respiratory infections and a key trigger of asthma exacerbations. No effective anti-HRV therapies exist, and vaccine efforts have been unsuccessful due to its extreme genetic and antigenic diversity, with over 160 known serotypes.
Enanta Pharmaceuticals Inc.’s phase IIb study of zelicapavir missed its primary endpoint in treating respiratory syncytial virus (RSV) but mined enough positive results to get the company to talk about advancing the once-daily oral treatment into further, larger studies.
Around the globe, fungal infections affect more than 1 billion people and account for several million deaths every year. They pose a particular problem in low- and middle-income countries, where antifungal drugs may be less available and, even if available, may prove ineffective because of fungal resistance. These considerations highlight the need for a next generation of antifungals.
Phase Scientific International Ltd. launched China’s largest clinical study for urine-based cervical cancer screening. If successful, the blood-based test could be the first non-invasive test for HPV.
RSS
